- Home
- AIRJW vs MRK Comparison
AIRJW vs MRK Comparison
Compare AIRJW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRJW
- MRK
- Stock Information
- Founded
- AIRJW N/A
- MRK 2000
- Country
- AIRJW United States
- MRK United States
- Employees
- AIRJW 17
- MRK N/A
- Industry
- AIRJW Blank Checks
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- AIRJW Finance
- MRK Health Care
- Exchange
- AIRJW Nasdaq
- MRK Nasdaq
- Market Cap
- AIRJW N/A
- MRK 198.5B
- IPO Year
- AIRJW N/A
- MRK N/A
- Fundamental
- Price
- AIRJW N/A
- MRK $81.00
- Analyst Decision
- AIRJW
- MRK Buy
- Analyst Count
- AIRJW 0
- MRK 15
- Target Price
- AIRJW N/A
- MRK $113.71
- AVG Volume (30 Days)
- AIRJW 19.1K
- MRK 18.0M
- Earning Date
- AIRJW 03-21-2025
- MRK 07-29-2025
- Dividend Yield
- AIRJW N/A
- MRK 4.00%
- EPS Growth
- AIRJW N/A
- MRK 667.14
- EPS
- AIRJW 4.07
- MRK 6.88
- Revenue
- AIRJW N/A
- MRK $63,922,000,000.00
- Revenue This Year
- AIRJW N/A
- MRK $2.42
- Revenue Next Year
- AIRJW N/A
- MRK $5.77
- P/E Ratio
- AIRJW $2.05
- MRK $11.77
- Revenue Growth
- AIRJW N/A
- MRK 4.10
- 52 Week Low
- AIRJW $1.11
- MRK $73.31
- 52 Week High
- AIRJW $1.32
- MRK $129.93
- Technical
- Relative Strength Index (RSI)
- AIRJW N/A
- MRK 54.36
- Support Level
- AIRJW N/A
- MRK $78.14
- Resistance Level
- AIRJW N/A
- MRK $83.07
- Average True Range (ATR)
- AIRJW 0.00
- MRK 1.84
- MACD
- AIRJW 0.00
- MRK 0.21
- Stochastic Oscillator
- AIRJW 0.00
- MRK 64.15
About AIRJW Montana Technologies Corporation Warrant
AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.